Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer

Fig. 5

M28z10 T cells showed strong antitumor activity in vivo in a pulmonary metastatic GC model. a Schematic representation of the experiments. b BLI of BGC-823-GL intravenously injected mice treated with GFP T or M28z10 T cells. Briefly, NSI mice received an i.v. injection of 1 × 106 BGC-823-GL cells. After 14 days, 5 × 106 M28z10 T cells or the equivalent number of GFP T cells were injected through the tail vein, and BLI was conducted on days 14, 23, and 35. c Statistical analysis of the ROI of BLI at each time point. Error bars denote the s.e.m., and the results were compared with two-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001. d Percentage of T cells in the PB of BGC-823-GL intravenously injected mice. Error bars denote the s.e.m., and the results were compared with an unpaired t-test. *P < 0.05; **P < 0.01; ***P < 0.001. e Survival curve of BGC-823-GL intravenously injected mice. The results were performed with Log-rank (Mantel-Cox) test. P value = 0.0027

Back to article page